Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors

Gemcitabine based treatment is currently a standard first line treatment for patients with advanced pancreatic cancer, however overall survival remains poor, and few options are available for patients that fail gemcitabine based therapy. To identify potential molecular targets in gemcitabine refract...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Biol Ther
Auteurs principaux: Samulitis, Betty K, Pond, Kelvin W, Pond, Erika, Cress, Anne E, Patel, Hitendra, Wisner, Lee, Patel, Charmi, Dorr, Robert T, Landowski, Terry H
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2014
Sujets:
Research Papers
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4623403/
https://ncbi.nlm.nih.gov/pubmed/25485960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.986967
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires